Navigation Links
Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team
Date:6/28/2011

in evaluating a promising new therapy."

According to the National Institutes of Health, 8-12 million people in the United States have PAD.  Although conventional stent and balloon treatments are available, achieving long-term effectiveness remains a challenge.  Drug-coated balloons may offer a much-needed new solution by combining the therapeutic simplicity of balloon angioplasty with the power of an anti-restenotic drug to help keep the artery open over time.  The DCB technology enables physicians to deliver the drug directly to the artery without leaving a permanent implant such as a stent behind.  

Executive Leadership Additions

Prior to joining Lutonix, Shawn McCormick previously served as Chief Financial Officer of ev3, Inc. and was instrumental in improving the company's operating performance, ultimately leading to a successful acquisition by Covidien.  Prior to ev3, Shawn spent 17 years with Medtronic in a variety of senior management roles including Vice President of Finance for the spinal division and Vice President, Corporate Development.

Leslie Trigg previously served as Chief Business Officer of AccessClosure, leading the sales and marketing efforts behind the launch of a new vascular closure device.  Prior to AccessClosure, she led the commercial introduction of a new PAD therapy as VP of Marketing for FoxHollow.  Leslie also has held commercialization roles of increasing responsibility at Guidant, Pro-Duct Health and Cytyc.  She currently serves on the board of directors for Cardiovascular Systems, Inc., a publicly traded medical device company in the peripheral vascular space.

"We are thrilled to be able to complement our strong regulatory, clinical, scientific and R&D capabilities with the extensive operating experience Shawn and Leslie bring to the company," said Dr. Dennis Wahr, CEO of Lutonix.   "Given their combined leadership track record
'/>"/>

SOURCE Lutonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lutonix Inc. Announces $20 Million Series B Financing
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 20, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... giving in 2014 to support a strong launch of ... Matters , and to improve the global communities where ... 2014, Edwards, global corporate giving will exceed $8 million, ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW Telbec/ - KLOX Technologies ... the following appointments: Todd Martensen ... the newly created role of Chief Commercial Officer, to ... using topical photoconverter gel for the treatment of chronic ... traumatic wounds, recently approved in Europe ...
(Date:11/21/2014)... Fla. , Nov. 20, 2014   Coqui ... become the first U.S. commercial producer of Molybdenum-99 (Mo-99), ... contract with INVAP to design its Medical ... Mo-99 is the parent isotope of Technetium-99, ... procedures worldwide. In 2012, Congress passed legislation making it ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... 2010 United Seating & Mobility (USM) , one ... excited to announce today that it has finalized a transaction ... The transaction applies to Fridley, MN serving the greater ... and Appleton, WI; RehabTECH will continue to operate its Illinois ...
... Dec, 2, 2010 SRI International, an independent ... it is collaborating with PhenoMatriX (PMX), a biotechnology ... drugs such as cisplatin and related analogues are ... have served as major weapons against solid tumors ...
Cached Medicine Technology:SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 2SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 3SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 4
(Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
(Date:11/22/2014)... 2014 PrettyTailor , an outstanding ... new big promotion. Customers can buy new dresses at ... can visit its website. , As a matter of ... dresses. It mainly provides four types of wedding outfits, ... flower girl dresses. It also provides a variety of ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... 2014 BambooFlooringChina.com is a famous ... proudly released its new collection of bamboo mats ; ... to 29% off. , According to the sales ... grass, making it a highly renewable resource. Their bamboo mats ... mixing color which comes from natural bamboo with caramel bamboo ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
Breaking Medicine News(10 mins):Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... Childhood cancer survivors diagnosed later with non-melanoma skin cancer ... tumor within 15 years, according to research led by ... percent of survivors in this Childhood Cancer Survivor Study ... skin cancer developed another more aggressive cancer within 15 ...
... June 2010 Elsevier, a world-leading healthcare and ... an agreement with Tarrytown, New York based InfoDesk ... for pharmaceutical and life science companies. The ... technological know-how paves the way for the development ...
... available in German . Early detection is ... every lump turns out to be a malignant tumor. To ... a biopsy and examine the removed tissue under the microscope. ... but also highly time consuming. Research scientists at the Fraunhofer ...
... 8, 2010) A University of Minnesota study definitively shows ... an increased life expectancy. The research is published in the ... The findings stem from the Program on Surgical Control ... at the University of Minnesota in 1975. Researchers evaluated 838 ...
... unique study with sunitinib suggest that it might be ... to treat HIV-positive cancer patients to achieve therapeutic benefit. ... treat their HIV, much more or considerably less chemotherapy ... NCI-supported AIDS Malignancy Consortium (AMC). The trial design ...
... 2010 The Institute for Research in Immunology and ... a new research funding model that brings together the ... accelerate the discovery of new anti-cancer therapeutics. Inspired by ... athletes at the Vancouver Winter Olympics, B2Discovery,s mission is ...
Cached Medicine News:Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution 2Health News:Detecting tumors faster 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 3Health News:B2Discovery: Entrepreneurs and researchers join forces to conquer cancer 2
... Activins are polypeptide hormones which belong ... superfamily. The TGF- superfamily is a ... which control many aspects of development, ... Other members incude TGF-s, bone morphogenetic ...
... also known as bone Gla protein, is ... is a major component of the noncollagenous ... osteoblasts in bone, with a small amount ... chondrocytes [1]. During bone formation, newly synthesized ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... suppress the secretion of FSH (follicle stimulating ... two distinct chains, or subunits (alpha and ... the alpha-subunit and betaA-subunit. Inhibin B consists ... dimeric forms of the molecule, containing both ...
Medicine Products: